Bavarian Nordic

For the first time, our vaccine against smallpox and Mpox is now available in a freeze-dried formulation.   This is a true testament to what a good private-public collaboration can do to keep people safe. Bavarian Nordic was contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) with a request to develop and supply a freeze-dried version of our smallpox and mpox vaccine to ensure better stockpiling of this life-saving vaccine. The freeze-dried formulation provides advantages in terms of transportation, storage conditions, and shelf life, all of which are important factors for long-term stockpiling   We are thrilled to announce this new formulation now has received FDA approval and the first vaccine will be delivered in 2025. Learn more by reading the press release here: https://lnkd.in/djxBceWi Together, we protect and save lives #BavarianNordic #ProtectingAndSavingLives #FDA #BARDA

We continue to expand our commercial footprint. The latest is the addition of our new UK subsidiary at the beginning of the year. Last year we also established BN entities in France and Belgium. This significant milestone enhances our presence and makes us available in even more markets. From Europe to North America and beyond, we enhance our presence and make our vaccines available to those who need them. We stay dedicated to strengthening disease prevention and shaping the future of vaccine innovation. Together, we protect and save lives. 

Tick season is here!     Did you know that the tick-borne encephalitis (#TBE) virus is transmitted from a tick bite within minutes? As tick season begins, it's crucial to be aware of TBE. What is TBE? TBE is an inflammation of the brain that can cause a range of neurological symptoms, which in some cases can lead to long-term consequences. Stay informed and protected, swipe through the carousel and find answers to frequently asked questions about TBE. Visit https://lnkd.in/dPJRrvJi to learn more about encephalitis! Stay safe this tick season.  #TickBornEncephalitis #ProtectingLivesEveryDay

Yesterday was an exciting day at our Kvistgaard production site in Denmark! We had the honour of hosting Africa CDC Director General, H.E. Dr. Jean Kaseya, along with other representatives. Among other things, we shared insights into the manufacturing capabilities of our mpox vaccine. Since our collaboration with Africa CDC expanded in 2024, we are working hard to ensure access to our mpox vaccine and enhance vaccine accessibility in Africa. The visit reaffirms our dedication to public health and commitment to protect and save lives. #ProtectingOurTomorrow #BavarianNordic #Partnership 

Our Chikungunya vaccine has officially arrived in the United States and is now commercially available! This marks a pivotal moment in our mission to combat chikungunya and help protect countless individuals from its impact. At Bavarian Nordic, our dedicated team has put in immense effort to develop and deliver this vaccine, and we are proud to contribute to the fight against this disease. Discover more insights here: https://lnkd.in/dDRCY35h Join us in the fight against chikungunya.   #ProtectingAndSavingLives #Chikungunya #Vaccine

Earlier this week, we had the pleasure of welcoming a delegation from the European Commission Health Emergency Preparedness and Response Authority (HERA) to our headquarters in Copenhagen. Among the delegation was Laurent Muschel, Head of the EU Commission Health Emergency Preparedness and Response Authority (HERA). Their visit highlighted the crucial role our public-private partnership plays in ensuring access to essential medical countermeasures, especially amidst the ongoing mpox Public Health Emergency of International Concern (PHEIC) and our shared efforts to control outbreaks in Africa. We look forward to continuing this vital collaboration and exploring new ways to enhance our efforts on medical countermeasures for mpox and smallpox. Together, we are protecting and saving lives. #BavarianNordic #ProtectingAndSavingLives #mpox #HERA

#IWD2025 On International Women’s Day, we want to highlight the actions our colleagues take to create an inclusive workplace. This year, we kicked off with a fantastic event with HBA EMEA at our Munich office focusing on women innovators. All actions at Bavarian Nordic are guided by our DNA #Boostedbytheteam and commitment to nurture an inclusive workplace where everyone feels safe, respected, and valued, regardless of background, identity, or beliefs. Meet some of our colleagues as they share their actions for inclusivity. What actions do you take? 👇 Let’s #AccelerateAction

Yet another milestone in our chikungunya journey is achieved. We are thrilled to share the acceptance of our submitted marketing authorization application by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for our chikungunya vaccine for persons aged 12 and older. The submission to MHRA was enabled by the recent positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), potentially supporting approval in the UK in the first half of 2025. With our recent organizational expansion into the UK, we are strongly positioned to leverage the strengths of our growing travel health portfolio to support the launch of our chikungunya vaccine. Read the full press release here: https://lnkd.in/db6myJCy #Chikungunya #TravelHealth #BavarianNordic #MHRA

2024 has been an extraordinary year of achievements. Yesterday, we published our 2024 annual report. Our CEO, Paul Chaplin, highlights our success in surpassing financial targets, swiftly responding to the mpox outbreak in the Democratic Republic of Congo, and expanding access to our life-saving vaccines. Together, we're not just tackling today's challenges but also paving the way for a healthier tomorrow. Dive into our 2024 annual report here: https://lnkd.in/dCzdDdgG #BavarianNordic #AnnualReport #ProtectingOurTomorrow

Our full-year results for 2024 are out! This past year has been one of unwavering dedication and remarkable achievements. 2024 marks our fifth consecutive year of growth and progress. As we step into 2025, we're eager to build on this strong foundation and continue pioneering vaccine innovation. With regulatory approvals secured in both the US and Europe, we're gearing up to launch our Chikungunya vaccine in key markets during the first half of the year. Today, we also announced two new pipeline candidates: one targeting Lyme disease and another targeting the Epstein-Barr Virus (EBV). These groundbreaking candidates are set to enter phase 1 trials in 2026, driving future growth and addressing critical medical needs. Dive into our 2024 annual report here: https://lnkd.in/dCzdDdgG #BavarianNordic #BavarianNordicAnnualReport2024 #AnnualReport #ProtectingAndSavingLives